27473375|t|Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later
27473375|a|In persons with multiple sclerosis (MS) self-efficacy positively affects health-related quality of life (HRQoL) and physical activity. In a previous study we observed that 6 months after an intensive 3- day social cognitive treatment (Can Do treatment) with the participation of support partners, self-efficacy and HRQoL had improved in persons with relapsing remitting MS (RRMS). Given the chronic nature of the disease, it is important to know whether these beneficial changes may last. Can Do treatment was given to 60 persons with MS and their support partners. At baseline and 12 months after treatment self-efficacy control, self-efficacy function, physical and mental HRQoL, anxiety, depression and fatigue were assessed via self-report questionnaires. Differences were tested via a paired t test. Of the 57 persons with MS that completed the baseline assessment and the 3- day treatment, 38 filled in the 12th month questionnaires (response rate 66.7 %), 22 with RRMS and 14 with progressive MS. In the RR group self-efficacy control had increased by 20.2 % and physical HRQoL by 15.0 %, and depression and anxiety had decreased by 29.8 and 25.9 %, respectively (all P < 0.05); the changes in mental HRQoL (+17 %) and fatigue (-20 %) failed to be statistically significant (P = 0.087, P = 0.080, respectively). In the progressive group no changes suggestive of improvement were seen. The findings suggest that a 3- day intensive social cognitive treatment (Can Do treatment) with the participation of support partners may have long lasting beneficial effects on the self-efficacy and HRQoL in persons with RRMS; and that improvements in anxiety and depression, not seen in the 6- month study, may yet develop at 12 months.
27473375	10	16	social	T169	C0728831
27473375	17	36	cognitive treatment	T061	C0009244
27473375	45	54	treatment	T169	C1522326
27473375	61	74	participation	T169	C0679823
27473375	86	94	partners	T098	C3887537
27473375	98	105	persons	T098	C0027361
27473375	111	149	relapsing remitting multiple sclerosis	T047	C0751967
27473375	151	162	observation	T058	C0700325
27473375	166	174	improved	T033	C0184511
27473375	175	188	self-efficacy	T041	C0600564
27473375	190	205	quality of life	T078	C0034380
27473375	207	214	anxiety	T033	C0003467
27473375	219	229	depression	T048	C0011570
27473375	232	236	year	T079	C0439234
27473375	246	253	persons	T098	C0027361
27473375	259	277	multiple sclerosis	T047	C0026769
27473375	279	281	MS	T047	C0026769
27473375	283	296	self-efficacy	T041	C0600564
27473375	297	307	positively	T033	C1446409
27473375	316	346	health-related quality of life	T078	C4279947
27473375	348	353	HRQoL	T078	C4279947
27473375	359	376	physical activity	T056	C0026606
27473375	401	409	observed	T169	C1441672
27473375	417	423	months	T079	C0439231
27473375	446	449	day	T079	C0439228
27473375	450	456	social	T169	C0728831
27473375	457	476	cognitive treatment	T061	C0009244
27473375	485	494	treatment	T169	C1522326
27473375	505	518	participation	T169	C0679823
27473375	530	538	partners	T098	C3887537
27473375	540	553	self-efficacy	T041	C0600564
27473375	558	563	HRQoL	T078	C4279947
27473375	568	576	improved	T033	C0184511
27473375	580	587	persons	T098	C0027361
27473375	593	615	relapsing remitting MS	T047	C0751967
27473375	617	621	RRMS	T047	C0751967
27473375	634	641	chronic	T079	C0205191
27473375	642	663	nature of the disease	T080	C0449786
27473375	703	713	beneficial	T081	C0814225
27473375	714	721	changes	T169	C0392747
27473375	739	748	treatment	T169	C1522326
27473375	765	772	persons	T098	C0027361
27473375	778	780	MS	T047	C0026769
27473375	799	807	partners	T098	C3887537
27473375	812	820	baseline	T081	C1442488
27473375	828	834	months	T079	C0439231
27473375	841	850	treatment	T061	C0087111
27473375	851	864	self-efficacy	T041	C0600564
27473375	865	872	control	T169	C2587213
27473375	874	887	self-efficacy	T041	C0600564
27473375	888	896	function	T169	C0542341
27473375	898	906	physical	T169	C0205485
27473375	911	917	mental	T041	C0025353
27473375	918	923	HRQoL	T078	C4279947
27473375	925	932	anxiety	T033	C0003467
27473375	934	944	depression	T048	C0011570
27473375	949	956	fatigue	T184	C0015672
27473375	962	970	assessed	T052	C1516048
27473375	975	986	self-report	T062	C2700446
27473375	987	1001	questionnaires	T170	C0034394
27473375	1003	1014	Differences	T080	C1705242
27473375	1020	1026	tested	T169	C0039593
27473375	1033	1046	paired t test	T170	C1709451
27473375	1058	1065	persons	T098	C0027361
27473375	1071	1073	MS	T047	C0026769
27473375	1079	1088	completed	T080	C0205197
27473375	1093	1101	baseline	T081	C1442488
27473375	1102	1112	assessment	T052	C1516048
27473375	1124	1127	day	T079	C0439228
27473375	1128	1137	treatment	T169	C1522326
27473375	1161	1166	month	T079	C0439231
27473375	1167	1181	questionnaires	T170	C0034394
27473375	1183	1191	response	T033	C1704632
27473375	1192	1196	rate	T081	C1521828
27473375	1214	1218	RRMS	T047	C0751967
27473375	1231	1242	progressive	T169	C0205329
27473375	1243	1245	MS	T047	C0026769
27473375	1254	1256	RR	T047	C0751967
27473375	1257	1262	group	T078	C0441833
27473375	1263	1276	self-efficacy	T041	C0600564
27473375	1277	1284	control	T169	C2587213
27473375	1289	1298	increased	T081	C0205217
27473375	1313	1321	physical	T169	C0205485
27473375	1322	1327	HRQoL	T078	C4279947
27473375	1343	1353	depression	T048	C0011570
27473375	1358	1365	anxiety	T033	C0003467
27473375	1370	1379	decreased	T081	C0205216
27473375	1433	1440	changes	T169	C0392747
27473375	1444	1450	mental	T041	C0025353
27473375	1451	1456	HRQoL	T078	C4279947
27473375	1469	1476	fatigue	T184	C0015672
27473375	1485	1491	failed	T169	C0231175
27473375	1498	1523	statistically significant	T081	C0237881
27473375	1569	1580	progressive	T169	C0205329
27473375	1581	1586	group	T078	C0441833
27473375	1590	1597	changes	T169	C0392747
27473375	1598	1611	suggestive of	T169	C0332299
27473375	1612	1623	improvement	T077	C2986411
27473375	1639	1647	findings	T169	C2607943
27473375	1648	1655	suggest	T078	C1705535
27473375	1666	1669	day	T079	C0439228
27473375	1680	1686	social	T169	C0728831
27473375	1687	1706	cognitive treatment	T061	C0009244
27473375	1715	1724	treatment	T169	C1522326
27473375	1735	1748	participation	T169	C0679823
27473375	1760	1768	partners	T098	C3887537
27473375	1778	1790	long lasting	T079	C1254367
27473375	1791	1801	beneficial	T081	C0814225
27473375	1802	1809	effects	T080	C1280500
27473375	1817	1830	self-efficacy	T041	C0600564
27473375	1835	1840	HRQoL	T078	C4279947
27473375	1844	1851	persons	T098	C0027361
27473375	1857	1861	RRMS	T047	C0751967
27473375	1872	1884	improvements	T077	C2986411
27473375	1888	1895	anxiety	T033	C0003467
27473375	1900	1910	depression	T048	C0011570
27473375	1931	1936	month	T079	C0439231
27473375	1952	1959	develop	T169	C1527148
27473375	1966	1972	months	T079	C0439231